Cabozantinib vs. Everolimus for Advanced Renal Cancer

Progression-free survival, the primary endpoint, was significantly longer with cabozantinib; incidence of grade 3 or 4 adverse events was higher.

The tyrosine kinase inhibitor (TKI) cabozantinib targets vascular endothelial growth factor receptors (VEGFRs), MET, and AXL, all of which are up-regulated in renal cancer. The drug is currently FDA-approved for treating patients with metastatic medullary thyroid cancer, and it has demonstrated intriguing antitumor activity in patients with progressive renal-cell disease following therapy with VEGF and mammalian target of rapamycin (mTOR) inhibitors (Ann Oncol 2014; 25:1603).

Now, investigators have conducted an industry-sponsored, phase III, randomized, open-label trial to compare the efficacy of cabozantinib (60 mg daily) versus everolimus (10 mg daily) in 658 good-performance status patients who had advanced renal cancer with a clear cell…

Reviewing Author

Robert Dreicer, MD, MS, FACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, FACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Cabozantinib vs. Everolimus for Advanced Renal Cancer

Topics

Reviewing Author